{"nctId":"NCT00365300","briefTitle":"Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD)","startDateStruct":{"date":"2006-09"},"conditions":["Gastroesophageal Reflux"],"count":129,"armGroups":[{"label":"Pantoprazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: pantoprazole"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"pantoprazole","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* term or post term infants beyond the neonatal period of an age greater than 28 days but less than or equal to 11 months\n* clinical diagnosis of GERD\n* weight greater than 2.5 kg and less than or equal to 15 kg\n\nExclusion Criteria:\n\n* known history of upper GI anatomic disorders\n* history of acute life-threatening medical conditions\n* clinically significant medical conditions or laboratory abnormalities","healthyVolunteers":false,"sex":"ALL","minimumAge":"28 Days","maximumAge":"11 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Patients Withdrawn From Study Due to Lack of Efficacy.","description":"Lack of efficacy defined as 1 or more of the following occurring during the double blind treatment-withdrawal phase: significant worsening of gastroesophageal reflux disease (GERD) symptoms frequency, a diagnostic test (e.g., endoscopy) demonstrating worsening of esophagitis, maximal antacid intake for â‰¥ 7 continuous days, or severe GERD symptoms based on physician's judgment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":129},"commonTop":["Upper respiratory infection","Fever","Diarrhea","Otitis media","Rhinitis"]}}}